Many studies have investigated whether @entity843 @entity165 can aid in diagnosis of @entity5 ( @entity5 ), and the results have varied considerably. To gain a more reliable answer to this question, we meta-analyzed the literature on using @entity843 @entity165 as diagnostic tests to help identify @entity5 . Literature databases were systematically searched for studies examining accuracy of @entity843 @entity165 for diagnosing @entity5 . Data on sensitivity, specificity, positive/negative likelihood ratio (PLR/NLR), and diagnostic odds ratio (DOR) were pooled using random effects models. Summary receiver operating characteristic (SROC) curves and area under the curve (AUC) were used to summarize overall test performance. At last, our meta-analysis included 8 studies involving 743 subjects. Summary estimates for @entity843 @entity165 in the diagnosis of @entity5 were as follows: sensitivity, 0.82 (95% CI 0.78 to 0.86); specificity, 0.90 (95% CI 0.87 to 0.93); PLR, 9.24 (95% CI 4.58 to 18.66); NLR, 0.16 (95% CI 0.08 to 0.32); and DOR, 66.96 (95% CI 18.83 to 238.11). The AUC was 0.96. The @entity843 @entity165 level is helpful for the diagnosis of @entity5 . Nevertheless, the results of @entity843 @entity165 assays should be interpreted in parallel with the results of traditional tests and clinical information.

Diagnostic accuracy of XXXX @entity165 concentration for malignant @entity843 : a meta-analysis.

@entity5 :: ('MESH:D009369', 'Disease') :: ['MRA', 'malignant related ascites'] @entity843 :: ('MESH:D001201', 'Disease') :: ['ascitic'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity843 :: (MESH:D001201,Disease) :: ['ascitic']
